

## MOLECULAR CANCER THERAPEUTICS

## TABLE OF CONTENTS

## HIGHLIGHTS

729 Selected Articles from This Issue

## SMALL MOLECULE THERAPEUTICS

731 Targeting Protein Translation by Rocaglamide and Didesmethylocaglamide to Treat MPNST and Other Sarcomas

Long-Sheng Chang, Janet L. Oblinger, Sarah S. Burns, Jie Huang, Larry W. Anderson, Melinda G. Hollingshead, Rulong Shen, Li Pan, Garima Agarwal, Yulin Ren, Ryan D. Roberts, Barry R. O'Keefe, A. Douglas Kinghorn, and Jerry M. Collins

742 Eribulin Suppresses Clear Cell Sarcoma Growth by Inhibiting Cell Proliferation and Inducing Melanocytic Differentiation Both Directly and Via Vascular Remodeling

Sho Nakai, Hironari Tamiya, Yoshinori Imura, Takaaki Nakai, Naohiro Yasuda, Toru Wakamatsu, Takaaki Tanaka, Hidetatsu Outani, Satoshi Takenaka, Kenichiro Hamada, Akira Myoui, Nobuhito Araki, Takafumi Ueda, Hideki Yoshikawa, and Norifumi Naka

755 Macrophage Syk-PI3K $\gamma$  Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression

**A C** Shweta Joshi, Kevin X. Liu, Muamera Zulcic, Alok R. Singh, Dylan Skola, Christopher K. Glass, P. Dominick Sanders, Andrew B. Sharabi, Timothy V. Pham, Pablo Tamayo, Daniel Shiang, Huy Q. Dinh, Catherine C. Hedrick, Guillermo A. Morales, Joseph R. Garlich, and Donald L. Durden

765 Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase

Myung-Kyu Jang, Tetsuo Mashima, and Hiroyuki Seimiya

777 Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck

Gabrielle van Caloen, Sandra Schmitz, Mariama El Baroudi, Xavier Caignet, Sébastien Pyr dit Ruys, Pierre P. Roger, Didier Vertommen, and Jean-Pascal Machiels

## LARGE MOLECULE THERAPEUTICS

790 Monoclonal Antibody Targeting Sialyl-di-Lewis<sup>a</sup>-Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential

**A C** Silvana T. Tivadar, Richard S. McIntosh, Jia Xin Chua, Robert Moss, Tina Parsons, Abed M. Zaitoun, Srinivasan Madhusudan, Lindy G. Durrant, and Mireille Vankemmelbeke

802 Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis

**A C** Ting Sun, Wenjia Zhang, Yuan Li, Zhengyu Jin, Yang Du, Jie Tian, and Huadan Xue

812 Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity

Zeliang Zheng, Ryuhei Okada, Hisataka Kobayashi, Tadanobu Nagaya, Junxia Wei, Qi Zhou, Fred Lee, Tapan K. Bera, Yun Gao, William Kuhlman, Chin-Hsien Tai, and Ira Pastan

822 Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies

Binbin Xie, Jianqin Wan, Xiaona Chen, Weidong Han, and Hangxiang Wang

835 Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding

**A C** Robyn J. Puro, Myriam N. Bouchlaka, Ronald R. Hiebsch, Benjamin J. Capoccia, Michael J. Donio, Pamela T. Manning, William A. Frazier, Robert W. Karr, and Daniel S. Pereira

# TABLE OF CONTENTS

## CANCER BIOLOGY AND TRANSLATIONAL STUDIES

- 847**    **Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma**  
Melanie A. Krook, Alexandria Lenyo, Max Wilberding, Hannah Barker, Mikayla Dantuono, Kelly M. Bailey, Hui-Zi Chen, Julie W. Reeser, Michele R. Wing, Jharna Miya, Eric Samorodnitsky, Amy M. Smith, Thuy Dao, Dorrelyn M. Martin, Kristen K. Ciombor, John Hays, Aharon G. Freud, and Sameek Roychowdhury
- 858**    **Extracellular Vesicle-Mediated *In Vitro* Transcribed mRNA Delivery for Treatment of HER2<sup>+</sup> Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity**  
**AC** Alexis V. Forterre, Jing-Hung Wang, Alain Delcayre, Kyuri Kim, Carol Green, Mark D. Pegram, Stefanie S. Jeffrey, and A.C. Matin
- 868**    **Phosphodiesterase 3A Represents a Therapeutic Target that Drives Stem Cell-like Property and Metastasis in Breast Cancer**  
Na Hao, Wenzhi Shen, Renle Du, Shan Jiang, Junyong Zhu, Yanan Chen, Chongbiao Huang, Yi Shi, Rong Xiang, and Yunping Luo
- 882**    **Targeting Phosphorylation of Y-Box-Binding Protein YBX1 by TASO612 and Everolimus in Overcoming Antiestrogen Resistance**  
Tomohiro Shibata, Kosuke Watari, Akihiko Kawahara, Tomoya Sudo, Satoshi Hattori, Yuichi Murakami, Hiroto Izumi, Junji Itou, Masakazu Toi, Jun Akiba, Yoshito Akagi, Maki Tanaka, Michihiko Kuwano, and Mayumi Ono
- 895**    **Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma**  
Karine Flem-Karlsen, Erin McFadden, Nasrin Omar, Mads H. Haugen, Geir Frode Øy, Truls Ryder, Hans Petter Gullestad, Robert Hermann, Gunhild Mari Mælandsmo, and Vivi Ann Flørenes
- 906**    **PIN1 Inhibition Sensitizes Chemotherapy in Gastric Cancer Cells by Targeting Stem Cell-like Traits and Multiple Biomarkers**  
Zhen-Zhen Zhang, Wei-Xing Yu, Min Zheng, Xin-Hua Liao, Ji-Chuang Wang, Da-Yun Yang, Wen-Xian Lu, Long Wang, Sheng Zhang, He-Kun Liu, Xiao Zhen Zhou, and Kun Ping Lu

- 920**    **Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model**  
Suzanne P. MacFarland, Koumudi Naraparaju, Radhika Iyer, Peng Guan, Venkatadri Kolla, Yuxuan Hu, Kai Tan, and Garrett M. Brodeur

## COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

- 927**    **Genetic Interactions and Tissue Specificity Modulate the Association of Mutations with Drug Response**  
Dina Cramer, Johanna Mazur, Octavio Espinosa, Matthias Schlesner, Daniel Hübschmann, Roland Eils, and Eike Staub
- 937**    **Clinical Application of Next-Generation Sequencing-Based Panel to *BRAF* Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies**  
Changhee Park, Miso Kim, Min Jung Kim, Hyeongmin Kim, Chan-Young Ock, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Jong-Il Kim, and Dae Seog Heo
- 945**    **Genomic and Expression Analyses Define MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer**  
Waleed S. Al Amri, Lisa M. Allinson, Diana E. Baxter, Sandra M. Bell, Andrew M. Hanby, Stacey J. Jones, Abeer M. Shaaban, Lucy F. Stead, Eldo T. Verghese, and Thomas A. Hughes
- 956**    ***KLF4* p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer**  
Song Ye, Xiaoge Hu, Chao Ni, Weiwei Jin, Yaping Xu, Lianpeng Chang, Huaixiang Zhou, Jiahong Jiang, and Liu Yang

## MODELS AND TECHNOLOGIES

- 966**    **Targeting Tumor Neoangiogenesis via Targeted Adenoviral Vector to Achieve Effective Cancer Gene Therapy for Disseminated Neoplastic Disease**  
**AC** Myungeun Lee, Zhi Hong Lu, Jie Li, Elena A. Kashentseva, Igor P. Dmitriev, Samir A. Mendonca, and David T. Curiel

**AC** AC icon indicates AuthorChoice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

# TABLE OF CONTENTS

## ABOUT THE COVER

Syk kinase has been well-described for its role in adaptive immunity and in this month's issue, Joshi and colleagues unveil its role in macrophage-driven immune suppression. In this cover image, a novel Syk inhibitor (SRX3188) docks into the active site of Syk kinase. SRX3188 forms hydrogen bonds with Ala451, Met450, and Arg498. Removal of a hydroxyl group improved the binding to PI3K, leading the authors to the chemotype of their dual Syk-PI3K inhibitor (SRX3207). By inhibiting the Syk-PI3K axis in tumors, the authors were able to generate anti-tumor immunity. Read the full article on page 755.

